Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HzMUC1-MMAE
- Development stage
- Preclinical
- Lead developer
- Wenzhou Medical University
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**HzMUC1-MMAE** is an investigational antibody-drug conjugate (ADC) consisting of a humanized monoclonal antibody targeting the cancer-associated glycoprotein Mucin 1 (MUC1), conjugated via a valine-citrulline dipeptide linker to the cytotoxic payload monomethyl auristatin E (MMAE). The antibody (HzMUC1) is specific to the region between extracellular subunits MUC1-N and MUC1-C. Upon binding to MUC1-expressing tumor cells, HzMUC1-MMAE is internalized, where intracellular release of MMAE disrupts microtubule polymerization, resulting in G2/M cell cycle arrest and apoptosis. Preclinical studies have demonstrated potent anti-tumor activity in MUC1-positive pancreatic cancer models and in trastuzumab-resistant HER2-positive breast cancer models[1][2][5].
- Brand names
- HzMUC1-MMAEHzMUC-1-MMAEHzMUC 1-MMAE
- Other names
- HzMUC1-MMAEHzMUC-1-MMAEHzMUC 1-MMAE
02
Targets
MUC1 (Mucin-1 Antigen)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on HzMUC1-MMAE.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HzMUC1-MMAE.